Herbal Dispatch Reports First Quarter 2026 Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, today reported its financial results for the three months ended March 31, 2026 and provided an update on the Company's strategic initiatives and operational progress. Strategic Transition Underway During the first quarter of 2026, Herbal
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-06-01 3:00 AM EDT | Herbal Dispatch Inc.
Theralase(R) Releases Q1 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-05-29 5:04 PM EDT | Theralase Technologies Inc.
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD,
Biotechnologies, Pharmaceutique, Santé
2026-05-29 4:30 PM EDT | Defence Therapeutics Inc.
NuGen Medical Devices Files Patent for Dual Spring Technology Enhancing Needle-Free Injection Performance
Toronto, Ontario--(Newsfile Corp. - May 28, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle free drug delivery, today announced the filing of a new patent application (Reference No. P105204NL) covering a new fluid injection technology designed to optimize pressure profiles in needle-free drug delivery systems. The new technology enables a controlled, multi-phase injection profile that delivers the high pressure needed for reli
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-28 1:43 PM EDT | NuGen Medical Devices Inc.
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdin
Biotechnologies, Pharmaceutique
2026-05-27 8:00 AM EDT | PharmaTher Holdings Ltd.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical ps
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-05-26 7:00 AM EDT | Optimi Health Corp.
Herbal Dispatch Obtains Export Development Canada (EDC) Insurance to Support Accelerating International Growth
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce that it has obtained export credit insurance coverage through Export Development Canada ("EDC") in support of its growing international cannabis export business. The EDC insurance coverage becomes active on June 1, 202
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-05-26 5:01 AM EDT | Herbal Dispatch Inc.
TempraMed Featured on Dr. Phil Show in National US Broadcast Highlighting the Risk of Temperature Exposure for Insulin and Other Medications
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed a medical technology innovator transforming how temperature sensitive medications are stored and managed, is pleased to announce that TempraMed is featured on the Dr. Phil Show in a national broadcast episode focused o
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-05-22 11:57 AM EDT | TempraMed Technologies Ltd.
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today closed its previously announced underwritten public offering (the "Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company issued 2,400,000 common s
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-05-21 1:07 PM EDT | Optimi Health Corp.
Conexeu Sciences Commences Trading on Nasdaq Under Ticker Symbol "CNXU"
Reno, Nevada--(Newsfile Corp. - May 21, 2026) - Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, announced it has officially commenced trading on the Nasdaq today under the ticker symbol "CNXU." The Company currently has 25,269,996 shares on an issued and outstanding basis and 35,238,222 shares on a fully diluted basis.
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-21 12:02 PM EDT | Conexeu Sciences Inc.
TMC Group Commissions New Capacity to Support Next-Generation Radiotheranostics
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - As demand for radiotheranostics continues to grow exponentially, TMC Group, a Canadian manufacturer of high-purity enriched stable isotopes, is commissioning new production lines this year. This will add 50 percent more capacity to help ensure reliable supply for radiopharmaceutical research, clinical development, and future commercialization. TMC Group will be exhibiting at the 2026 Society of Nuclear Medicine and Molecular
Technologies, Biotechnologies, Produits chimiques, Pharmaceutique
2026-05-21 10:00 AM EDT | TMC Group
Herbal Dispatch Completes Export of 261kg of Medical Cannabis to Europe
Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis e-commerce and distribution platform, is pleased to announce the successful completion of a 261-kilogram international medical cannabis export shipment to Europe. The shipment represents another significant milestone in the continued expansion of Herbal Dispatch's international exp
Pharmaceutique, Cannabis, Dispensaires de cannabis
2026-05-21 5:01 AM EDT | Herbal Dispatch Inc.
Theralase(R) Closes C$4.8 Million Offering
Toronto, Ontario--(Newsfile Corp. - May 20, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has closed its previously announced brokered private placement offering ("Brokered Offering
Technologies, Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique
2026-05-20 11:06 AM EDT | Theralase Technologies Inc.
Sym Sciences Awarded $50,000 Grant to Advance IND-Ready Cannabinoid Research Platform
New York, New York--(Newsfile Corp. - May 20, 2026) - Sym Sciences announced today that it has been awarded a $50,000 grant from the to support the development of standardized, IND-ready cannabinoid materials for clinical research. The funding will enable Sym Sciences to expand its university research network and accelerate the preparation of regulatory-grade cannabinoid formulations designed for NIH-funded studies. The initiative is focused on streamlining the pathway from product deve
Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-05-20 8:25 AM EDT | Sym Sciences
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the "Company" or "Optimi"), a commercial-stage pharmaceutical company focused on manufacturing and distributing finished psychedelic drug products, today announced the pricing of its underwritten public offering (the " Offering") in connection with the uplisting of its common shares to the Nasdaq Capital Market. The Company is offering 2,400,000 common shares at a public o
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-05-20 8:00 AM EDT | Optimi Health Corp.
Optimi Health gibt Preisfestsetzung für überzeichnetes öffentliches Angebot in Höhe von 15 Mio. US-$ und Nasdaq-Uplisting bekannt
Vancouver, British Columbia--(Newsfile Corp. - Mittwoch, 20. Mai 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (das "Unternehmen" oder "Optimi"), ein pharmazeutisches Unternehmen im kommerziellen Stadium mit Fokus auf die Herstellung und den Vertrieb fertiger psychedelischer Arzneimittelprodukte, gab heute die Preisfestsetzung seines gezeichneten öffentlichen Angebots (das "Angebot") im Zusammenhang mit dem Uplisting seiner Stammaktien an den Nasdaq Capital Market bek
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-05-20 8:00 AM EDT | Optimi Health Corp.
PreveCeutical Announces Extension of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its news releases dated May 12, 2026 and April 22, 2026, it has extended the closing of its private non-brokered private placement (the "Offering") of units of the Company (each, a "Unit") to raise gross proceeds of $1,000,000 to June 12, 2026 and intend
Biotechnologies, Pharmaceutique, Santé
2026-05-19 7:36 PM EDT | PreveCeutical Medical Inc.
Richards Group Inc. Announces May 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - May 19, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended May 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on May 29, 2026 and will be payable on June 12, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends are
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-05-19 9:48 AM EDT | Richards Group Inc.
Maxwell Biosciences' Claromers Destroy Epstein-Barr
Austin, Texas--(Newsfile Corp. - May 19, 2026) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired, broad spectrum small molecules called Claromers®, today announces Claromers destroy Epstein-Barr virus, according to a third-party lab study.
Biotechnologies, Pharmaceutique
2026-05-19 9:00 AM EDT | Maxwell Biosciences, Inc.